Patents by Inventor Sean Caenepeel

Sean Caenepeel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EX VIVO SYSTEMS AND METHODS FOR DETERMINING THE EFFECT OF A DRUG OR OTHER AGENT ON A TISSUE
    Publication number: 20220326220
    Abstract: Provided are ex vivo systems and methods of predicting the response of a drug or other agent on a tissue. In some embodiments, the systems and methods comprise cutting a tissue into tissue fragments, adding a drug or other agent to the tissue fragments based on an estimated tumor content, and performing an ex vivo measurement on the tissue fragments.
    Type: Application
    Filed: June 7, 2022
    Publication date: October 13, 2022
    Inventors: Jonathan Daniel Oliner, Neil Anthony, Sean Caenepeel, Laura Catherine Funk Hrycyniak, John Rafter, Tomasz Zal
  • Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers
    Publication number: 20220280495
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: September 9, 2021
    Publication date: September 8, 2022
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • EX VIVO SYSTEMS AND METHODS FOR DETERMINING THE EFFECT OF A DRUG OR OTHER AGENT ON A TISSUE
    Publication number: 20220205976
    Abstract: Provided are ex vivo systems and methods of predicting the response of a drug or other agent on a tissue. In some embodiments, the systems and methods comprise cutting a tissue into tissue fragments, adding a drug or other agent to the tissue fragments based on an estimated tumor content, and performing an ex vivo measurement on the tissue fragments.
    Type: Application
    Filed: December 30, 2021
    Publication date: June 30, 2022
    Inventors: Jonathan Daniel Oliner, Neil Anthony, Sean Caenepeel, Laura Catherine Funk Hrycyniak, John Rafter, Tomasz Zal
  • Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue
    Patent number: 11366101
    Abstract: Provided are ex vivo systems and methods of predicting the response of a drug or other agent on a tissue. In some embodiments, the systems and methods comprise cutting a tissue into tissue fragments, adding a drug or other agent to the tissue fragments based on an estimated tumor content, and performing an ex vivo measurement on the tissue fragments.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: June 21, 2022
    Assignee: Elephas Biosciences Corporation
    Inventors: Jonathan Daniel Oliner, Neil Anthony, Sean Caenepeel, Laura Catherine Funk Hrycyniak, John Rafter, Tomasz Zal
  • Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
    Patent number: 10881648
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 5, 2021
    Assignee: AMGEN INC.
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers
    Publication number: 20190290630
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: December 21, 2018
    Publication date: September 26, 2019
    Inventors: Sean Caenepeel, Jude Canon, Paul Hughes, Jonathan D. Oliner, Richard J. Rickles, Anne Y. Saiki
  • Biomarkers and use of MET inhibitor for treatment of cancer
    Patent number: 10328062
    Abstract: The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.
    Type: Grant
    Filed: April 3, 2015
    Date of Patent: June 25, 2019
    Assignee: Amgen, Inc.
    Inventors: Sean Caenepeel, Angela Coxon, Zhiqiang Du, Paul Hughes, Robert Loberg, Gataree Ngarmchamnanrith, Beate Sable
  • BIOMARKERS AND USE OF MET INHIBITOR FOR TREATMENT OF CANCER
    Publication number: 20170182016
    Abstract: The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.
    Type: Application
    Filed: April 3, 2015
    Publication date: June 29, 2017
    Inventors: Sean CAENEPEEL, Angela COXON, Zhiqiang DU, Paul HUGHES, Robert LOBERG, Gift NGARMCHAMNANRITH, Beate SABLE
  • COMBINATION THERAPY INCLUDING AN MDM2 INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
    Publication number: 20160287569
    Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
    Type: Application
    Filed: November 11, 2014
    Publication date: October 6, 2016
    Applicant: AMGEN INC.
    Inventors: Sean CAENEPEEL, Jude CANON, Paul HUGHES, Jonathan D. OLINER, Anne Y. SAIKI, Richard J. RICKLES
  • Novel kinases
    Publication number: 20070202107
    Abstract: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK's and STK's have been identified and their protein structure predicted.
    Type: Application
    Filed: April 21, 2006
    Publication date: August 30, 2007
    Inventors: David Whyte, Gerard Manning, Sean Caenepeel
  • Novel human protein kinases and protein kinase-like enzymes
    Publication number: 20060204994
    Abstract: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the PTK's and STK's have been identified and their protein structure predicted.
    Type: Application
    Filed: March 6, 2006
    Publication date: September 14, 2006
    Inventors: Gregory Plowman, David Whyte, Gerard Manning, Sucha Sudarsanam, Ricardo Martinez, Sean Caenepeel
  • Novel proteases
    Publication number: 20050287546
    Abstract: The present invention relates to protease polypeptides, nucleotide sequences encoding the protease polypeptides, as well as various products and methods useful for the diagnosis and treatment of various protease-related diseases and conditions.
    Type: Application
    Filed: January 19, 2005
    Publication date: December 29, 2005
    Inventors: Gregory Plowman, David Whyte, Sean Caenepeel, Glen Charydczak, Gerard Manning, Sucha Sudarsanam
  • Novel kinases
    Publication number: 20050125852
    Abstract: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of protein and lipid kinase families have been identified and their protein structure predicted.
    Type: Application
    Filed: May 7, 2004
    Publication date: June 9, 2005
    Inventors: Sean Caenepeel, Gerard Manning, Glen Charydczak, Igor Grigoriev
  • Novel Kinases
    Publication number: 20040197792
    Abstract: The present invention relates to kinase polypeptides, nucleotide sequences encoding the kinase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various kinase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the of PTK's and STK's have been identified and their protein structure predicted.
    Type: Application
    Filed: July 15, 2003
    Publication date: October 7, 2004
    Applicant: SUGEN, INC.
    Inventors: David Whyte, Gerard Manning, Sean Caenepeel
  • Mammalian protein phosphatases
    Publication number: 20020090703
    Abstract: The present invention relates to phosphatase polypeptides, nucleotide sequences encoding the phosphatase polypeptides, as well as various products and methods useful for the diagnosis and treatment of various phosphatase-related diseases and conditions. Through the use of a bioinformatics strategy, mammalian members of the MAP kinase phosphatase PTP's and STP's have been identified and their protein structure predicted.
    Type: Application
    Filed: May 30, 2001
    Publication date: July 11, 2002
    Inventors: Gregory D. Plowman, Ricardo Martinez, David Whyte, Gerard Manning, Sucha Sudarsanam, Sean Caenepeel, Ron Hill, Peter Flanagan
  • Novel proteases
    Publication number: 20020064856
    Abstract: The present invention relates to protease polypeptides, nucleotide sequences encoding the protease polypeptides, as well as various products and methods useful for the diagnosis and treatment of various protease-related diseases and conditions.
    Type: Application
    Filed: June 26, 2001
    Publication date: May 30, 2002
    Inventors: Gregory Plowman, David Whyte, Sean Caenepeel, Glen Charydczak, Gerard Manning, Sucha Sudarsanam